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Multicentric Carpotarsal Osteolysis Is Caused
by Mutations Clustering in the Amino-Terminal
Transcriptional Activation Domain of MAFB
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Multicentric carpotarsal osteolysis (MCTO) is a rare skeletal dysplasia characterized by aggressive osteolysis, particularly affecting the
carpal and tarsal bones, and is frequently associated with progressive renal failure. Using exome capture and next-generation sequencing
in five unrelated simplex cases of MCTO, we identified previously unreportedmissensemutations clustering within a 51 base pair region
of the single exon ofMAFB, validated by Sanger sequencing. A further six unrelated simplex cases withMCTOwere also heterozygous for
previously unreported mutations within this same region, as were affected members of two families with autosomal-dominant MCTO.
MAFB encodes a transcription factor that negatively regulates RANKL-induced osteoclastogenesis and is essential for normal renal devel-
opment. Identification of this gene paves the way for development of novel therapeutic approaches for this crippling disease and
provides insight into normal bone and kidney development.Next-generation sequencing presents a new approach for
disease-gene mapping in either small pedigrees or in small
numbers of affected individuals and has been used to
uncover the underlying cause for several skeletal dyspla-
sias.1–4 Multicentric carpotarsal osteolysis (MCTO [MIM
166300]) is a rare skeletal dysplasia characterized by
progressive bone resorption (osteolysis), predominantly
(although not exclusively) of the carpal and tarsal bones.
The early clinical appearance can mimic polyarticular
juvenile idiopathic arthritis; however, subsequent clinical
and radiographic appearances are characteristic (see
Figure 1). Affected individuals can also have subtle
craniofacial abnormalities (triangular faces, micrognathia,
and exophthalmos), and many develop a progressive
nephropathy leading to end-stage renal failure. Both
simplex cases and families with autosomal-dominant
inheritance have been reported.5–16 However, the re-
sponsible genetic defect has remained elusive. Mutations
in MMP2 [MIM 120360], responsible for the autosomal-
recessive Torg-Winchester syndrome [MIM 259600]17–19
that is also characterized by excessive bone resorption,
have not been identified in patients with MCTO.20 Here,
we report identification of the underlying genetic cause
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autosomal-dominant MCTO through the Queensland
Bone Dysplasia Registry at the University of Queensland
Centre for Clinical Research. Each individual had classical
radiographic features of MCTO (complete destruction of
carpal bones but relatively well-preserved metacarpals
and phalanges) (Figure 1). Five of the 11 simplex cases
had undergone renal transplantation. Of the remaining
six, three had markedly impaired renal function but did
not yet require dialysis. Three individuals all of whom
were very young (7 years old or younger), had no evidence
of renal dysfunction. The affected individuals in the two
families with autosomal-dominant MCTO had no
evidence of renal dysfunction. The study was approved
by the University of Queensland Ethics Committee, and
all subjects or their respective guardians gave informed
written consent.
We performed whole-exome sequencing in five unre-
lated individuals withMCTO. Genomic DNAwas extracted
from peripheral blood samples via standard protocols. We
used 5 mg DNA to construct DNA sequencing libraries
with Illumina’s DNA sample preparation kit for paired-
end sequencing per the manufacturer’s protocol. We used
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Figure 1. Typical Clinical and Radio-
graphic Appearance of MCTO
(A) Complete destruction of carpal bones
with relatively well-preserved metacarpals
and phalanges (individual 17.3).
(B) Hand X-rays of individual 15.3 at (a) 3,
(b) 8, and (c) 10 years old, respectively.
Note the absence of carpal bones and
progressive osteolysis of proximal end of
metacarpal bones, whereas the distal end
and the phalanges remain relatively well
preserved.Roche/Nimblegen SeqCap EZ Exome Library v1.0 kits
(Roche/Nimblegen) according to the manufacturer’s
protocol. Efficiency of sequence capture was assessed
via quantitative real-time PCR with standard control
primers as recommended by the manufacturer. Each DNA
sequencing library was quality checked and quantified
with Agilent 2100 Bioanalyser and DNA 1000 chip kits.
We standardized the DNA concentration for sequencing
to 10 nM. Each DNA library was individually sequenced
via a 56 paired-end read sequencing protocol with a single
flow cell lane on an Illumina Genome Analyzer II and with
the manufacturer’s reagents.
Initial base calling was performedwith the Illumina Data
Analysis Pipeline software (CASAVA 1.7). Sequence data
were aligned to the current build of the human genome
(hg19, released February 2009) with the Novoalign
alignment tool (V2.07.09 1); sequence alignment files
were converted with SAMtools (v0.1.14) and Picard tools
(v1.42).21 SNPs and indels were called with the Genome
Analysis Toolkit (GATK v5506)22 and were annotated
with ANNOVAR.23 An average of 1.96 Gb of sequence per
individual (range 1.48–2.38 Gb) was generated, withThe American Journal of Humanmean on-target (exons 5 200 bp)
sequence of 87.0% (range 85.5%–
88.1%). Mean depth of exomic
coverage was 50-fold (range 37.0–
60.5) with 84.9% and 75.9%
achieving 10-fold and 15-fold
coverage, respectively (mapping and
coverage statistics and detailed base
calling information is presented in
Tables S1 and S2, available online).
Custom scripts with R and Bio-
conductor were used to analyze and
filter the sequencing data. SNPs and
indels with good quality reads were
retained (minimum depth of cov-
erage for SNP calling, greater than
10-fold for homozygous SNPs and
greater than 15-fold for heterozygous
SNPs). Additionally, we used the
GATK-provided quality parameters:
we included SNPs/indels with values
QUAL > 50, QD > 0.5, HRUN < 5,and SB < 0.1 (defined as: QUAL, combined recalibrated
quality score at the SNP position; DP, sequencing depth
at the SNP position; QD, QUAL/DP ratio at the SNP posi-
tion; HRun, maximal length of the homopolymer run;
SB, strand bias at the SNP position). We retained SNPs
and indels with potentially damaging consequence (non-
synonymous SNV, splicing, frameshift substitution, stop-
gain SNV, and stoploss SNV based on either RefSeq or
UCSC transcripts). We excluded SNPs observed in the
National Center for Biotechnology Information (NCBI)
dbSNP (release 132), 1000 Genomes, 1000 Genomes small
indels (called with the DINDEL program), the SNPs of 46
genomes release by Complete Genomics and 16 other
whole exomes from control samples run internally with
the same capture technology that was used in this project.
We assessed the five sequenced individuals for heterozy-
gous carriage of either a single previously unreported
nonsynonymous SNP shared by all individuals or a previ-
ously unreported nonsynonymous SNP in each individual
within a common gene. After quality filtering (detailed in
Table 1), a single gene was identified,MAFB (v-maf muscu-
loaponeurotic fibrosarcoma oncogene ortholog B [avian]Genetics 90, 494–501, March 9, 2012 495
Table 1. Summary of Identified Variants from Exome Sequencing
SKDP 1.3 SKDP 15.3 SKDP 20.4 SKDP 28.3 SKDP 8.3
Genes with Variants
in All Subjects
Number of variants identified 58,734 58,565 59,195 50,507 55,802 8,771
Number of variants after quality control
and coverage filters
24,920 27,818 28,804 22,545 24,795 4,974
Nonsynonymous variants, indels in exons,
or splice sites after quality control and filtering
6,255 6,752 6,831 6,217 6,322 1,630
Previously unreported nonsynonymous variants,
indels in exons, or splice sites after quality control
and filtering
185 155 168 174 237 3a
aVariants in three genes remained. Two of these were dinucleotide repeats in splice sites and did not fit appropriate autosomal-dominant inheritance pattern. Thus
variants in only one remaining gene (MAFB) fitted all the criteria.[MIM 608968]), in which each individual was heterozy-
gous for a single previously unreported missense mutation
in a highly conserved region (Figure 2).
We used Sanger sequencing to validate the observed
mutations. Because of the presence of the adjacent large
deletion polymorphism (rs71854600), PCR primers were
designed to amplify 170 bp of the coding region surround-
ing the mutation hotspot. The primer sequences for initial
PCR amplification were as follows: MAFB_ShF 50-(M13-21)
GCTCAAGTTCGACGTGAAGA30, and MAFB_ShR 50-
CGAGGTGTGTCTTCTGTTCG30. Sequencing was per-
formed with standard M13 (21) sequencing primer and
BigDye v3.1 cycle sequencing reagents, and capillary elec-
trophoresis was performed on Genetic Analyzer 3130
(Applied Biosystems).
In addition to the five probands who had undergone
exomic sequencing, we also sequenced the same region
in their (clinically unaffected) parents; a further six unre-
lated simplex cases with MCTO and their parents (with
a single exception, individual 81.3, for whom no parental
DNA sample was available); and all available family
members of two families with autosomal-dominant inher-
itance of MCTO (Figure 3). We also sequenced 164 unre-
lated white European controls. Sanger sequencing
confirmed the mutations identified through exomic
sequencing in the five probands. Further, the six additional
simplex cases with MCTO also demonstrated previously
unreported heterozygous missense mutations in the same
region of MAFB (Figure 2). None of the parents of the
affected probands carried the mutations present in their
child, demonstrating that these are previously unreported
autosomal-dominant mutations in the affected individ-
uals. In the two families with autosomal-dominant inheri-
tance of MCTO, heterozygous missense mutations were
also demonstrated in the same region and segregated
with disease status (Figure 3). None of the 164 control
samples carried any mutations in this region (328 alleles).
The location of the mutated amino acids within the
protein domain is shown in Figure 4. We used three
SNP function prediction algorithms (Polyphen [Poly-
Phen-2 v2.1.0r367]; SIFT, PMut) to predict the effect of
the observed previously unreported SNPs upon protein496 The American Journal of Human Genetics 90, 494–501, March 9function. All observed mutations were predicted to be
probably or possibly damaging with Polyphen (full results
presented in Table 2). We assessed conservation of this
region of MafB against UCSC genome browser data and
demonstrated conservation of this region back to the zebra
fish (Figure 2).
Thus we have identified previously unreported missense
mutations, all predicted to be damaging to protein function
and clustering within a narrow region of the single exon of
MAFB in all cases of MCTO; we have also demonstrated
segregation of mutations with disease in two multigenera-
tional families with autosomal-dominant MCTO. MAFB
codes for a member of the V-MAF musculoaponeurotic
fibrosarcoma oncogene family of transcription factors. It
is a single exon gene with two known transcripts, a 3.0 kb
transcript expressed ubiquitously and a shorter 1.8 kb
transcript expressed predominantly in bone marrow and
skeletalmuscle,24 coding for a 323 amino acid protein (Uni-
Prot: Q9Y5Q3). In common with other Maf proteins, the
carboxy-terminal of MafB contains a well-conserved basic
region for DNA binding (amino acid position 238–264)
and a leucine zipper domain involved in dimerization
(amino acid position 266-287). The amino-terminal region
(amino acid positions 1-110) is a Pro-Ser-Thr- rich acidic
transcriptional activation domain.24 Overall homology
between human andmouseMAFB is 93% and that between
human andmouseMafB is 97%, and the region containing
the observed mutations is highly conserved (Figure 2).
MafB is known to play critical roles in both osteoclast
differentiation and activation25 and renal development,26
consistent with the major phenotypic features of MCTO.
It is expressed in myeloid cells in the bone marrow and is
essential for normal hematopoieisis. Specifically, MafB
suppresses erthyroid differentiation while upregulating
myeloid differentiation to monocytes and macro-
phages.27 Osteoclasts are derived from hematopoietic
stem cells of the macrophage/monocyte lineage under
the combined influence of receptor activator of nuclear
factor kB ligand (RANKL) and macrophage colony stimu-
lating factor (M-CSF). MafB negatively regulates RANKL-
induced osteoclastogenesis.25 In bone marrow-derived
monocyte/macrophage cell cultures, MafB overexpression, 2012
Figure 2. Sanger Sequencing and
Comparative Genomics of MAFB
(Upper panel) Sanger sequencing ofMAFB,
demonstratingmutations in all 11 simplex
cases with MCTO. Labels in bold refer to
the original five probands sequenced
with NGS.
(Lower panel) Protein coding and compar-
ative genomics of MAFB (derived from
UCSC genome browser).inhibited osteoclastogenesis by interfering with the key
transcription factors normally activated by RANKL,
whereas reduced MafB expression enhanced osteoclasto-
genesis. Conversely, RANKL downregulated expression of
MafB.25 Thus, MafB might regulate the development of
pluripotent myeloid precursors by enhancing macrophage
differentiation while repressing osteoclastogenesis. MafB is
itself regulated by the transcription factor CCAAT/
enhancer-binding protein b (C/EBPb); and osteoclastic
bone resorption is increased in mice with C/EBPb defi-
ciency and in mice expressing only the short isoform of
C/EBPb in both of which MafB expression levels are atten-
uated.28,29
The observed mutations in MAFB all lie within a short
region of the amino-terminal transcriptional activation
domain (amino acids 54-71; see Table 2 and Figure 4). Of
note, amino-terminal truncation of MAFB (residual
amino-acids 195-311 fused to the N terminus) exerted
a dominant negative effect upon myeloid colony forma-
tion and macrophage differentiation.27 The observedThe American Journal of Humanheterozygous missense mutations in
MAFB in individuals with MCTO
have a dominant effect; however,
whether the mechanism for this is
haploinsufficiency or a dominant
negative effect requires further study.
In common with other large Maf
proteins, MafB is phosphorylated by
glycogen synthase kinase-3. The con-
served phosphorylation sites shared
by Maf proteins lie in the same region
as the observed mutations; there
are four mutations predicted to
affect putative phosphorylation sites
(amino acids 54, 62, 66, and 70). Mu-
tations of the corresponding amino
acids inMafAprevented phosphoryla-
tion and decreased its transcriptional
activity.30 It is possible that the muta-
tionsweobservedmighthavea similar
effect upon MafB phosphorylation
and subsequent function. However,
functional studies are required to
confirm such speculation.
It is not clear why the bony
changes in MCTO are seen predomi-nantly in the carpal and tarsal bones. Systemic bone
mineral density (BMD) has not been studied comprehen-
sively in patients with MCTO; however, one case report
noted osteopaenia in a child before significant renal
dysfunction had developed.16 In adult patients with
advanced renal failure, it is not possible to partition the
effects of renal osteodystrophy from direct systemic bone
effects from MAFB mutations. Whether polymorphisms
in MAFB are associated with variation in BMD in the
normal population is unclear. In our GWAS of 2,055 post-
menopausal women with either extremely high or low
BMD, three SNPs in MAFB were associated with lumbar
spine BMD with p value < 103 (not significant at
a genome-wide level),31 a finding sufficiently suggestive
to warrant further investigation in larger data sets.
Patients with MCTO commonly develop renal impair-
ment and frequently progress to end-stage kidney disease.
Renal biopsy is often only obtained at a late stage of
disease, by which time nonspecific findings of glomerulo-
sclerosis and severe tubulointerstitial fibrosis dominateGenetics 90, 494–501, March 9, 2012 497
Figure 3. Sanger Sequencing and Family
Trees for Families 82 and 83
(A) Family 82.
(B) Family 83.
Black indicates known affected and white
indicates known unaffected; a question
mark indicates unknown status.the biopsy appearance. However, two studies report renal
biopsies obtained from children with MCTO and early
renal dysfunction. One child, with isolated proteinuria,
had focal and segmental glomerulosclerosis with distor-
tion, fusion, and effacement of the podocyte foot
processes.16 Another child, only 2 years old but with
hypertension, proteinuria, and mildly elevated serum
creatinine, had a normal biopsy with light microscopy,
but electron microscopy also showed abnormal fusion of
the podocyte foot processes and discrete abnormalities of
the glomerular basement membrane.32 MafB is essential
for normal development of podocyte foot processes26,33
and is expressed in both the podocyte late in renal develop-
ment and in the mature glomerulus. MafB/ homozy-
gous knockout mice have renal dysgenesis, including loss
of normal foot processes of podocytes, abnormal glomer-498 The American Journal of Human Genetics 90, 494–501, March 9, 2012ular differentiation with decreased
mature glomeruli, tubular dysgenesis
due to abnormal tubular survival,
and renal cysts. The mice have
decreased renal expression of neph-
rin, podocin, and CD2AP, critical
proteins for normal podocyte devel-
opment, and glomerular func-
tion.26,33 Although abnormalities in
these basement membrane proteins
have not been studied in patients
with MCTO, the histopathological
features that have been demonstrated
in homozygous mice are consistent
with the renal biopsy findings
observed in patients with MCTO
and renal impairment.Renal disease was present in most but not all patients
in our cohort. Individuals 43.3, 81.3, and 22.3 have
as yet no evidence of renal disease. However, these
patients are only 3, 6 and 7 years old, respectively,
and it is as yet unclear whether their renal function
will remain normal. Of note, individual 81.3 has a
unique mutation (c.176C>T [p.Pro59Leu]); and in-
dividuals 22.3 and 43.3 share the same mutation
(c.211C>T [p.Pro71Ser]) although at the same location
as another individual who has manifested renal disease.
The affected individuals in family 82 and family 839
(who carry the same mutation, c.161C>T [p.Pro54Leu]),
many of whom are adults, do not have renal disease,
with the exception of individual 1.2 in Family 83
who at a very old age developed renal dysfunction of
unknown aetiology. Thus it seems likely that MAFBFigure 4. Schematic picture of MafB,
showing protein domains and positions
of the observed mutations in individuals
and families with MCTO
Table 2. List of Variants Observed in MAFB (NM_005461.3), and Predicted Protein Changes
Individual Variant
Amino Acid
Substitution
Functional Prediction
Polyphen PMut SIFT
SKDP 81.3 c.176C>T p.Pro59Leu probably damaging pathologic tolerated
SKDP 20.4 c.184A>C p.Thr62Pro possibly damaging pathologic tolerated
SKDP 25.3 c.188C>G p. Pro63Arg probably damaging pathologic damaging
SKDP 27.3 c.197C>G p.Ser66Cys probably damaging neutral damaging
SKDP 15.3 c.206C>T p.Ser69Leu possibly damaging neutral tolerated
SKDP 8.3 c.208T>G p.Ser70Ala probably damaging neutral damaging
SKDP 17.3 and 28.3 c.209C>T p.Ser70Leu probably damaging pathologic damaging
SKDP 22.3 and 43.3 c.211C>T p.Pro71Ser probably damaging neutral tolerated
SKDP 1.3 c.212C>T p.Pro71Leu probably damaging Pathologic damaging
SKDP 82 and 83 (affected members) c.161C>T p.Pro54Leu probably damaging pathologic damagingmutations are also responsible for MCTO in the absence
of renal disease.
Patients with MCTO also have a subtle craniofacial
abnormalities that include micrognathia, a slim nose,
maxillary hypoplasia, and consequent exophthalmos.8,12
A recent GWAS of cleft lip with and without cleft palate
found significant association with multiple variants near
MAFB and expression studies demonstrated MafB expres-
sion in palatal tissue.34 Cleft lip and/or palate have not
been reported as a feature of patients with MCTO.
Studies in mice have suggested that MAFB plays
important roles in pancreatic b cell development and in
hindbrain development. MCTO is not known to be
associated with pancreatic or central nervous system
abnormalities, although these have not been investigated
in detail.
Of the ten separate mutations observed, all were pre-
dicted to be probably or possibly damaging (Table 2). The
protein structure of MafB is only established for the
fragment of protein interacting with its DNA recognition
motif, Cmare (amino acids 238–264).35 The mutations
we observed cluster in a narrow region of the transitional
activation domain where the protein structure is not yet
established, although of note the protein domains in this
regions are highly evolutionarily conserved (Figure 2).
The function prediction algorithm PolyPhen predicts
that all the variants are damaging or possibly damaging.
We tested two additional algorithms Pmut and SIFT
(Table 2). Pmut predicts four of the variants to be neutral;
however, three of these calls have low reliability according
to their own scoring criteria (all 0/10 except for S70A
scored at 7/10).
Skeletal dysplasias highlight important pathways in
bone of relevance to the general population and to
common bone diseases such as osteoporosis. For example,
the identification of SOST [MIM 605740] as the gene
underlying sclerosteosis [MIM 269500]36 and van
Buchem’s disease [MIM 239100]37 has lead to the develop-The Amement of anti-sclerostin antibodies as a treatment for osteo-
porosis.38 For patients with MCTO, bisphosphonates have
not proven useful in treatment to date. Our data suggest
that it might be worth targeting MafB signaling instead
in these patients. Anti-RANKL antibody therapy is now
available for the treatment of osteoporosis39 and could be
considered for treatment of at least the bone disease that
characterizes the MCTO phenotype.
In conclusion, we have identified previously unreported
missense mutations clustering in a narrow region ofMAFB
in 11 unrelated simplex cases and in two families with
MCTO. MAFB is known to play a critical role in regulation
of osteoclastogenesis and in normal renal development,
making this a highly plausible gene underlying this skel-
etal dysplasia. This study opens up the possibility of new
therapeutic options in these patients and other patients
with excessive osteoclastic activity.Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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